Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia

BACKGROUND: Eltrombopag is a thrombopoietin receptor agonist with excellent treatment outcomes in immune thrombocytopenia (ITP). Here, we analyzed the dose of eltrombopag required to achieve and maintain safe platelet counts in Korean ITP patients. METHODS: Adult refractory ITP patients (<30,000...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood Res
Autores principales: Kim, Yeo-Kyeoung, Lee, Seung-Sin, Jeong, Sung-Hoon, Ahn, Jae-Sook, Yang, Deok-Hwan, Lee, Je-Jung, Kim, Hyeoung-Joon
Formato: Artigo
Lenguaje:Inglês
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2015
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4377333/
https://ncbi.nlm.nih.gov/pubmed/25830126
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5045/br.2015.50.1.19
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares